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1. Introduction 
The incidence of breast cancer has increased greatly in Israel over the past decade. It is 
estimated that in Israel in 2009 approximately 4800 new patients will suffer from breast cancer. 
Despite recent advances in the diagnosis and treatment of breast cancer, this disease 
continues to be a major cause of death. One of the biggest challenges in breast cancer 
treatment is bone metastasis. Breast cancer cells are capable of migrating to the bone 
marrow and utilizing the marrow microenvironment to remain quiescent. The 
preprotachykinin-1 (PPT-I) gene encodes for the tachykinin peptides, which interact with 
neurokinin (NK) receptors. Studies have correlated this interaction with breast cancer cells 
integration into the bone marrow and breast cancer progression (1). 
Environmental and psychological stresses have been shown to be associated with an 
increased incidence of cancer in man and animals. Stress-induced neuron chemical 
hormonal and immunological changes have been shown to influence tumor development. 
Stress may promote mammary carcinogenesis by affecting the neuroendocrine system and I 
or immune function. Neuroendocrine affects may involve changes in adrenocortical steroids 
or opioid peptides which may exert their effects by altering immune functions (2). 
One of the risk factors for breast cancer is the increased amount of adipose tissue after 
menopause which elevates estradiol production. 
The adrenergic system plays a role in regulating energy balance through thermogensis and 
lipid mobilization from brown or white adipose tissues (3). 
The human fat cells are equipped with adrenergic receptors (adreno receptors) ǃ1, ǃ2 
(ADRB1/2) and ǃ3 (ADRB3) (4). 
2. Physiology 
The degree of affinity for adrenaline (epinephrine) is ǃ2 > ǃ1> ǃ3 and the noradrenaline 
(norephinephrine) it is ǃ1 ≥ ǃ2 > ǃ3 (5). 
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Norepinephrine, epinephrine and dopamine are members of biogenic amines. They share a 
common precursor - tyrosine. It is converted to L-dopa by tyrosine hydroxylase and L-dopa 
is converted to dopamine by dopa decarboxylase. In the nerve terminal dopamine is 
converted to norepinepherine. 
If phenylethanol - N - methyl transferase (PNMT) is present norepinephrine is methylated to 
epinephrine. Adrenergic neurons secrete norepinephrine because they contain dopamine ǃ 
hydroxylase. 
Adreno receptors may be activated by norepinephrine, which is released from adrenergic 
neurons, or by epinephrine, which is secreted into the circulation by the adrenal medulla. 
Among the sympathetic adrenoreceptors, receptor type is related to function (6). 
In addition to their role as neurotransmitters and stress hormones, catecholamines play a 
trophic role in the control of cell replication and differentiation in target cells that express 
adrenergic receptors. In some cell lines, ǃ -adrenergic stimulation elicits a small, 
promotional effect on cell replication, whereas in others, stimulation of these receptors and 
the consequent rise in intracellular cAMP levels inhibits mitosis. ǃ -adrenoreceptors on 
cancer cells, thus, recapitulate both the promotional and inhibitory roles of these receptors 
in cell replication seen in the development of normal cells. 




Target organ Mechanism of action 
ǂ1 Vascular smooth muscle, skin, renal and splanchnic 
gastrointestinal tract, bladder sphincter, iris, radial  
muscle, sphincters 
IP3, increase of 
intracellular [Ca2+] 
ǂ2 Gastrointestinal tract wall, presynaptic adrenergic 
neurons 
Inhibition of adenylyl 
cyclase, decrease cAMP 
ǃ1 Heart, salivary gland, adipose tissue, kidney stimulation of adenylyl 
cyclase, increase cAMP 
ǃ2 Va Vascular smooth muscle of skeletal muscle, GI 
wall, 
GI bladder wall, bronchioles 
stimulation of adenylyl 
cyclase, increase cAMP 
 
The ǃ -adrenergic agonist isoproterenol, stimulates mammary epithelial cell division in 
vitro, as well as the development of end bud structures in the mammary gland of ovary 
ectomized mice from which arise the mammary carcinoma induced by administration of 
dimethylbenz (ǂ) anthracene (DMBA). Specific ǃ -adrenergic receptors of the ǃ2 subtype are 
present in epithelial cell membranes from lactating mammary gland tissue. 
The hormonal modulations of receptors which affect uterine contractility correlates with the 
onset of psychological responses of the uterus such as contraction and relaxation. In analogy 
with the uterus the regulation of the physiological status of the mammary gland is achieved 
by modification of endocrine, autonomic and mechanical factors during adolescence, the 
menstrual cycle, pregnancy parturition and lactation. The mammary gland, as other paired 
endocrine glands (adrenals, ovaries and testes), receives sympathetic innervations. 
High levels of ǃ -adrenergic receptors are measured as palpable mammary tumors, reaching 
a maximal concentration well before the actual increase in tumor mass. The hormone 
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sensitivity of the tumoral ǃ -adrenergic receptor is further confirmed by the high receptor 
concentration measured in progressing mammary tumors. 
Stress effects may involve ACTH, glucocorticoids, catecholamines, prolactin, opioids and 
immunosuppression, all factors crucially involved in tumor growth. 
Catecholestrogens, their receptors, together with their catabolizing enzyme, catecholo-
methyltransferease(COMT), are locally formed in both normal and neoplastic mammary 
tissues. COMT levels are significantly increased in the cytosol of malignant tumor cells than 
in the cytosol of benign tumor or normal cells (7). 
2.2 Adrenoceptors and cancer 
Recent studies in human cancer cell lines in animal models have shown that the growth of 
adenocarcinomas of the lungs, pancreas and colon are under ǃ -adrenergic control (8-12). 
The expression of ǃ -adrenergic receptors has been correlated with the over-expression of 
the arachidonic acid-metabolizing enzymes cyclooxygenase-2 (COX-2) and lipoxygenases 
(LOX) in adenocarcinomas of lungs, colon, prostate and pancreas. Inhibitors of these 
enzymes have been identified as cancer preventive agents in animal models. 
2.3 Adrenoceptors and breast cancer 
Many of breast adenocarcinomas over express COX-2 and / or LOX (13). 
This may say that a subset of breast cancers may also be under ǃ adrenergic control. 
Studies have demonstrated that three estrogen-responsive and three non-estrogen 
responsive human cell lines derived from breast adenocarcinoma show a reduction in DNA 
synthesis in response to beta-blockers or inhibitors of the arachidonic acid- metabolizing 
enzymes COX-2 and 5-LOX. 
Another study analysis by reverse transcription polymerase chain reaction (RT-PCR) 
revealed expression of ǃ 2-adrenergic receptors in all six breast cancer cell lines tested 
(MDA-MB-361, ZR-75-l, MCF-7, MDA-MB-453, MDA-MB-468, MDA-MB-4355). 
ǃ 1 receptors were not found in two estrogen non-responsive cell lines (MDA-MB4355, 
MDA-MB-453 (14). 
It was found that the second messenger cAMP may be a growth promoter for mouse, rat 
and human mammary epithelioma (15, 16). 
The effects of cAMP observed in malignant cells are involved in redifferentiation amounting 
to renormalization of number of properties including morphology, adhesive properties, 
lectin agglutination, cell movement and biochemical functions (17). 
A correlation between ǃ adreno receptor (ǃ -AR) stimulation and estrogen and progesterone 
receptor functions was found in human breast cancer (18). 
ǃ 2-adrenergic stimulation induced cell proliferation in hormone-dependent human breast 
cancer cell line (C6-5), but without involving the female steroid hormone receptor system (18).  
In C6-5 cells, the presence of functional ǃ -AR's could be reasonable related to cell 
proliferation when exposed to different concentrations of clenbuterol, a ǃ 2-AR agonist 
showed increased cell proliferation without involving significantly lower than that induced 
by oestradiol ǃ adreno receptor-mediated inhibition of DNA synthesis was not shared by 
another cancer cell line, C6 rat glioma, that expresses a different ǃ -receptor subtype a lower 
levels whereas found that MDA-MB-231 cells express ǃ 2-receptors exclusively, C6 cell 
express primarily the ǃ1 subtype (19). 
In mammary tissue there are data that support a role of catecholamines in the control of 
many cellular activities. Initial experiments indicate epinephrine sensitive adenylate cyclase 
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activities in 7, 12 - dimethylbenz (ǂ) anthracene - induced mammary carcinoma. Two groups 
have demonstrated the presence of ǃ -adrenergic receptors (ǃ -AR) from mammary glands 
of lactating rats. ǃ -adrenergic compounds stimulated the enzyme leading to the generation 
of cAMP and its activation was completely abolished by the ǃ -AR blocking drug 
propranolol. 
ǃ -adrenergic - related increases in cAMP formation undoubtedly influence lactose 
production by the acinar secretory end pieces. The initial response to ǃ -AR is usually an 
increase in adenylate cyclase activity resulting in an increased cellular cAMP concentration. 
Among the epithelial, endocrine, and secretory cancer cell lines that express 
adrenoreceptors, MDA-MB-231 human breast cancer cells exhibit comparatively high 
concentrations. It is thus of critical interest that stimulation of these receptors leads to 
immediate inhibition of DNA synthesis and, with prolonged exposure, reductions in the 
total number of cancer cells: inhibition of DNA synthesis is a reliable predictor of 
chemotherapeutic responses in breast cancer cells. 
In prostate or breast cancer cells stimulated by EGF or androgen or estradiol, small peptides 
(6-10 amino acids) derived from ER or AR sequences involved in the receptor interaction 
with Src, prevent AR/ER/Src association, Src/Erk pathway stimulation, cyclin D1 
expression and DNA synthesis. The peptide action is restricted to cells expressing the 
steroid receptors and to signals mediated by these receptors. Remarkably, the peptides do 
not modify. Although there has been no systematic screening of breast cancer cell lines for ǃ 
-adrenergic expression these receptors have identified in both estrogen-dependent type and 
estrogen-independent type, including C6-5, BF 20, T47-D, VHB-1 and MCF-7. Regardless of 
the ancillary mechanisms involved in ǃ -receptor — mediated inhibition of mitosis in MDA-
MB-231 breast cancer cells, the fact that inhibition does not disappear with receptor down 
regulation and desensitization raises the possibility for therapeutic strategies employing 
receptor agonists, alone or in combination with glucocorticoids and phosphodiesterase 
inhibitors (20). 
Screening of human cancers for the presence of ǃ -adrenoreceptors or other cAMP —linked 
neurotransmitter receptors may establish new treatment strategies. 
ǃ -adrenergic receptors (ǃ -AR's) were identified in CG-5 breast cancer cells using a 
radiometric assay. The total ǃ -AR concentration was measured using the highly potent ǃ -
adrenergic antagonist CGP 12 177, and the densities of ǃ -AR subtypes were discriminated 
in the presence of highly selective unlabelled ligands (CGP 207 12A and ICI 118551). 
The second messenger cAMP was found to be a growth promoter for mouse, rat and human 
mammary epithelioma and its levels are elevated in several breast carcinomas. 
The effects of cAMP observed in malignant cells are often involved in redifferentiation, 
amounting to apparent renormalization of a number of properties including morphology, 
adhesive properties, lectin agglutination, cell movement and biochemical functions. A 
correlation between ǃ -AR stimulation and estrogen and progesterone receptor functions 
was found in human breast cancer. 
It was observed that ǃ2-adrenergic stimulation induced cell proliferation in a hormone-
dependent human breast cancer cell line (CG-5), but without involving the female steroid 
hormone receptor system. 
CG-5 cells (mammary breast cell cancer cell line) contain measurable concentrations of 
specific ǃ AR's coupled to adenylate cyclase. The characteristics of these ǃ -AR's, identified 
by binding and competition assays, are those of ǃ 1-AR and ǃ2 -AR subtypes. ǃ 2-AR 
concentration is significantly higher than ǃ 1-AR concentration in CG-5 cell membranes. 
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Negligible concentrations of ǃ -AR's were found in MCF-7 breast cancer cells from which 
CG-5 cells are derived. In C6-5 cells the presence of functional ǃ -AR's could be reasonably 
related to cell proliferation when exposed to different concentrations of clenbuterol, a ǃ 2-AR 
agonist, showed increased cell proliferation without involving steroid hormone receptors. 
Although the enhancement of CG-5 cell growth was significantly lower than that induced 
by estradiol the presence of functional ǃ -AR’s (with the prevalence of the ǃ 2-AR subtype) 
in tumor cell line suggests that ǃ -adrenergic stimulation and resulting cAMP production 
may be responsible for CG-5 cell proliferation. 
Medroxyprogesterone acetate (MPA) is one of the most widely used compounds in the 
endocrine therapy of advanced breast cancer in women. The mechanisms underlying the 
antitumor activity of MPA are poorly understood. This steroid presents a high affinity for 
progesterone (PgR) as well as for androgen (AR) and glucocorticoid receptors (GR) in 
human mammary tumors. 
The most easily explained effects of MPA are related to its glucocorticoid-like action. 
Suppression of adrenal function by MPA is believed to be caused both by an inhibitory 
action at the pituitary level and by direct inhibition of steroidogenesis. 
In addition to ER and PgR, which are the most widely used markers of differentiated 
endocrine functions in breast cancer; AR and GR (Glucocorticoid receptors) are present in a 
substantial number of mammary tumors and established cell lines. The ZR-75-1 human 
breast cancer cell line is an unusually appropriate system to study the direct effect of MPA 
on cell growth. ZR-75-1 cells contain functional receptors for estrogens, androgens, 
progestins and glucocorticoids. Progestins inhibit ZR-75-1 cell proliferation exclusively in 
presence of estrogens and in absence of insulin.  
MPA further decreased the growth of ZR-75- 1 cells co-incubated with maximally inhibitory 
concentrations of either 5 alpha-dihydrotestosterone ((DHT) or dexamethasone (DEX) 
although at about 300-fold higher MPA concentrations with DHT-treated than with DEX-
treated ZR-75-1 cells, thus demonstrating a highly predominant androgenic effect. The main 
action of MPA on ZR-75-1 human breast cancer cell growth is due to its androgen receptor-
mediated inhibitory action. 
The majority of breast cancer are adenocarcinomas and many of them over express 
cyclooxygenase - 2 (COX-2) (9) and/or lipoxygenases (LOX). This raises the possibility that 
comparable to findings in adenocarcinomas of the lungs, pancreas, colon and prostate, and a 
subset of breast cancer may also be under beta adrenergic control. Studies have 
demonstrated that three estrogen-responsive and three non-estrogen responsive human cell 
lines derived from breast adenocarcinomas demonstrated a significant reduction in DNA 
synthesis in response to beta-blockers or inhibitors of the arachidonic acid metabolizing 
enzymes COX-2 (9) and LOX-5.  
Analysis by reverse transcription polymerase chain reaction (RT-PCR) revealed expression 
of ǃ2-adrenergic receptors in all six breast cancer cell tested (MDA-MB- 361, ZR-75-1, MCF-7, 
MDA-MB -453, MDA-MB-468, MDA-MB-435S) whereas ǃ1 receptors were not found in two 
estrogen non-responsive cell lines (MDA-MB-435S, MDA-MB-453). 
Expression of mRNA that encodes a G-protein coupled inward by rectifying potassium 
channel 1 (GIRK1) (7) has been shown in 40% breast cancer samples. This expression of 
GIRK1 was associated with a more aggressive clinical behavior. Previous studies indicated 
that the beta-adrenergic agonist isoproterenol stimulates growth. GIRK currents have been 
shown to be increased in cells stimulated with the beta-adrenergic agonist isoproterenol in 
rat atrial myocytes transferred with ǃ1 or ǃ2 receptors. Two po1ymorphisms in the ǃ2 or ǃ3 
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adrenergic receptors were found to be correlated with decreased risk for breast cancer, 
suggesting an important role of this receptor family in the genesis of breast cancer. 
In C6-5 cells (16, 19) the presence of functional ǃ -AR's could be reasonable related to cell 
proliferation when exposed to different concentration of clenbuterol, a ǃ 2-AR agonist 
showed increased cell proliferation without involving significantly lower than that induced 
by estradiol ǃ adreno receptor-mediated inhibition of DNA synthesis was not shared by 
another cancer cell line, C6 rat glioma, that expresses a different ǃ -receptor subtype a lower 
levels whereas (20) found that MOA-MB-23 1 cells express ǃ 2-receptors exclusively, C6 cell 
express primarily the ǃ1 subtype. 
There is increasing evidence that describes a histamine role in normal and cancer cell 
proliferation. To better understand the importance of histamine in breast cancer 
development, the expression of histamine H3 (H3R) and H4 (H4R) receptors and their 
association with proliferating cell nuclear antigen (PCNA), histidine decarboxylase (HDC) 
and histamine content were explored in mammary biopsies. Additionally, we investigated 
whether H3R and H4R were implicated in the biological responses triggered by histamine in 
MDA-MB-231(20) breast cancer cells. 
Centrally assess estrogen receptor (ER) and progesterone receptor (PgR) levels by 
immunohistochemistry and investigate their predictive value for benefit of chemo-
endocrine compared with endocrine adjuvant therapy alone in two randomized clinical 
trials for node-negative breast cancer. 
Low levels of ER and PgR are predictive of the benefit of adding chemotherapy to endocrine 
therapy. Low PgR may add further predictions among pre-and perimenopausal but not 
postmenopausal patient whose tumors express ER. 
The majority of all breast cancers are hormone responsive, traditionally defined by he 
expression of oestogen receptor (ER) alpha and/or progesterone receptors. In contrast to 
ERalpha, the clinical significance of the relatively recently identified ERbeta is still unclear. 
ERalpha and ERbeta seem to be differentially associated to clinicopathological parameters, 
and this would support the fact that they might have different functions in vivo. 
In prostate or breast cancer cells stimulated by EGF or androgen or estradiol, small peptides 
(6-10 amino acids) derived from ER or AR sequences involved in the receptor interaction with 
Src, prevent AR/ER/Src association, Src/Erk pathway stimulation, cyclin D1 expression and 
DNA synthesis. The peptide action is restricted to cells expressing the steroid receptors and to 
signals mediated by these receptors. Remarkably, the peptides do no modify! 
Epidermal growth factor (EGF), transforming growth factor-alpha (TGFalpha), 
amphiregulin (AREG), betacellulin (BTC), heparin-binding EGF-like growth factor (HB-
EGF),epiregulin (EREG) and neuregulins1-4 (NRG1-4) were quantified in 363 tumors by 
real-time reverse transcription-polymerase chain reaction using TaqMan probes. 
Paget's disease (PD) of the breast as well as the vulva is a rare condition, therefore anti-
hormonal therapy is not indicated. The high frequency of Her-2/neu and COX-2 
overexpression, however, suggests that these molecules could be therapeutically relevant in 
patients with PD. 
Epidemiological evidence indicates that the association between body weight and breast 
cancer risk may differ across menopausal status as well as the estrogen receptor (ER) and 
progesterone receptor (PR) tumor status.  
The relation between body weight and breast cancer risk is critically dependent on the 
tumor's ER/PR status and the woman's menopausal status. Body weith control is the 
effective strategy for preventing ER+PR+ tumors after menopause. 
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ErbB3 transactivation can make tumor cells resistance to ErbB1/ErbB2 targeting drugs. This 
urges for a reliable method to determine cel surface ErbB3 levels, but their hands iodinated 
NRG1 beta is unstable and tends to underestimate the umber of ErbB3 receptors in a radio-
receptor assay. 
Furthermore, they show by differential competition with unlabled NRG/YYDLL and 
betacellulin that the number of ErbB3 and ErbB4 receptors can be quantified separately on 
cultured human breast cancer cells. 
Esterogen receptor (ER) antagonists have been widely used for breast cancer treatment, but 
the efficacy and drug resistance remain to be clinical concerns. The purpose of this study 
was to determine whether the extracts of coptis, an anti-inflammatory herb, improve the 
anticancer efficacy of ER antagonists, Their results showed that the combined treatment of 
ER antagonists and the crude extract of coptis or its purified compound berberine conferred 
synergetic growth inhibitory effect on MCF-7 cells (ER+), but not on MDA-MB-231 cells (R-). 
Similar results were observed in the combined treatment of fulvestrant, a specific aromatase 
antagonist. Analysis of the expression of breast cancer related genes indicated the EGFR, 
HER2, bci-2, and COX-2 were significantly downregulated, while IFN-beta and p21 were 
remarkably upregulated by herberine.  
The negative association between he oestrogen receptor (ER) and the human epidermal 
growth factor 2 (HER-2) in breast cancer travels in both directions. ER+ tumors are less 
likely HER-2+ and HER-2+ are less likely ER+. Studies the age-related 
immunohistochemical (IHC) expression of ER, HER-2 in 2,227 tumors using age as a 
continuous variable (21). 
Estrogen receptors (ERs) are overexpressed in human breast cancers (BCs) and associated 
with differentiated tumors and with a more favorable prognosis (22-34). 
Paradoxically, ERs mediate the mitogenic action of estrogens in human BC cells and the 
efficacy of antiestrogens in adjuvant therapy of primary tumors. The exact mechanism 
underlying the ER protection against cancer progression to metastasis remains to be 
investigated. They show that ERs decrease invasiveness of BC cells. Detailed studies 
revealed that the unliganded and the E2-activated ERs decrease cancer cell invasion in vitro 
through two distinct mechanisms. In the presence of ligand, ERalpha inhibits invasion 
through a mechanism requiring the functional ERalpha domains involved in the 
transcriptional activation of target genes. 
Hormone receptors play important roles in breast cancer. The expression of hormone 
receptors in breast cancer was investigated to evaluate the importance of hormone receptors 
in the clinicopathology of breast cancer. 
Androgen receptor (AR), estrogen receptor (ER) and progesterone receptor (PR) expression 
characteristics were evaluated using immunohistochemistry stain, comparing patient age, 
tumor size and axillary lymph node status for 23 pure mucinous and 105 non-mucinous 
infiltrating ductal carcinomas in the human female breast. 
Findings revealed that mucinous carcinoma samples from the breast show distinct 
clinicopathologic and hormone receptor expression features compared to non-mucinous 
carcinoma.  
There is increasing evidence that describes a histamine role in normal and cancer cell 
proliferations. To better understand the importance of histamine in breast cancer 
development, the expression of histamine H3 (H3R) nad H4 (H4R) receptors and their 
association with proliferating cell nuclear antigen (PCNA), histidine decarboxylase (HDC) 
and histamine content were explored in mammary biopsies. Additionally, we investigated 
whether H3R and H4R were implicated in the biological MDA-MB-231 breast cancer cells. 
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ǃ -adrenergic receptors (ǃ -AR's) were identified in C6-5 breast cancer cells using a 
radiometric assay. The total ǃ -AR concentration was measured using the highly potent ǃ -
adrenergic antagonist CGP 12 177, and the densities of ǃ -AR subtypes were discriminated 
in the presence of highly selective unlabelled ligands (CGP 20712A and ICI 118551). 
The second messenger cAMP was found to be a growth promoter for mouse, rat and human 
mammary epithelioma and its levels are elevated in several breast carcinomas. 
It was observed that ǃ 2-adrenergic stimulation induced cell proliferation in a hormone 
dependent human breast cancer cell line (CG-5), but without involving the female steroid 
hormone receptor system. CG-5 cells (mammary breast cell cancer cell line) contain 
measurable concentrations of specific ǃ AR's coupled to adenylate cyclase. The 
characteristics of these ǃ -AR's, identified by binding and competition assays, are those of ǃ 
1-AR and ǃ 2-AR subtypes. ǃ 2-AR concentration is significantly higher than ǃ 1-AR 
concentration in CG-5 cell membranes. Negligible concentrations of ǃ –AR's were found in 
MCF-7 breast cancer cells from which CG-5 cells are derived. 
Although the enhancement of CG-5 cell growth was significantly lower than that induced 
by estradiol the presence of functional ǃ -AR’s (with the prevalence of the ǃ2- subtype AR) in 
tumor cell line suggests that ǃ -adrenergic stimulation and resulting cAMP production may 
be responsible for CG-S cell proliferation.  
Medroxyprogesterone acetate (MPA) is one of the most widely used compounds in the 
endocrine therapy of advanced breast cancer in women. 
The mechanisms underlying the antitumor activity of MPA are poorly understood. 
This steroid presents a high affinity for progesterone (PgR) as well as for androgen (AR) and 
glucocorticoid receptors (GR) in human mammary tumors. 
The most easily explained effects of MPA are related to its glucocorticoid-like action. 
Suppression of adrenal function by MPA is believed to be caused both by an inhibitory 
action at the pituitary level and by direct inhibition of steroidogenesis. 
In addition to ER and PgR, which are the most widely used markers of differentiated 
endocrine functions in breast cancer; AR and GR are present in a substantial number of 
mammary tumors and established cell lines. The ZR-75-1 human breast cancer cell line is an 
unusually appropriate system to study the direct effect of MPA on cell growth. ZR-75-1 cells 
contain functional receptors for estrogens, androgens progestins and glucocorticoids. 
Progestins inhibit ZR-75- 1 cell proliferation exclusively in presence of estrogens and in 
absence of insulin. 
MPA further decreased the growth of ZR-75-1 cells co-incubated with maximally inhibitory 
concentrations of either 5 alpha-dihydrotestosterone (DHT) or dexamethasone (DEX) at 
about 300-fold higher MPA concentrations with DHT-treated than with DEX-treated ZR-75- 
1 cells, thus demonstrating a highly predominant androgenic effect. The main action of 
MPA on ZR-75-1 human breast cancer cell growth is due to its androgen receptor-mediated 
inhibitory action. 
3. Summary 
In normal and malignant mammary tissues there are data supporting a role for 
catecholeamines in the control of many cellular activities. The presence of functional ǃ-AR's 
in human mammary cell lines has been described. All six breast cell lines express either 
GIRK2 or GIRK4 indicating that functional GIRK potassium channels are possible in these 
cancer cell lines. The direct control of cell proliferation shown in vitro could eventually open 
new avenues for adjuvant therapies in the treatment of breast diseases. 
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